enGene Therapeutics Inc.

ENGN

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2.

About the company

Country: CanadaPrice: $2.41Market Cap: $161.5M

Investment snapshot

0%positive consensus

Scored 1d ago

Positive

BUY / PASS

Neutral / negative

4 / 12

NEUTRAL / FAIL

Median fair value

$431.44

+17802.1% vs price

Models with upside

4 / 17

Positive margin of safety

Strongest signal

ENGN undervalued: all 4 models price fair value above $2.41 (median $431.44)

Key risk

No clean pass — all 8 investors flag at least one growth criterion

Framework analysis

Verdict	Meaning
BUY	Positive purchase signal: the framework's buy requirements are met.
PASS	The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRAL	Neither a positive nor negative conclusion. It does not mean to hold an existing position.
FAIL	The company does not clear the framework's requirements.
Ranked	Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

Metric	Graham Defensive Value	Buffett Quality Compounder	Lynch GARP	Greenblatt Magic Formula	Piotroski F-Score	Dreman Contrarian Value	Munger Quality Focus	Pabrai Dhandho Framework	Akre Three-Legged Stool	Marks Risk-Aware Value	Ackman Activist Value	Templeton Global Bargain Hunter	Sleep Scale Economies Shared	Asness Systematic Factors	Neff Low-P/E Total Return	Schloss Asset-Value Discipline	O'Shaughnessy Systematic Factor Composite
Verdict	FAIL	FAIL	FAIL	FAIL · Rank #2832 (Top 91.4%)	FAIL	FAIL	NEUTRAL	NEUTRAL	FAIL	FAIL	FAIL	FAIL	FAIL	NEUTRAL	FAIL	FAIL	NEUTRAL
Score
Analysis	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…
Intrinsic Value (annual)		N/A	N/A	N/A	N/A		N/A	N/A	N/A		N/A		N/A	N/A	N/A	N/A	N/A
Margin of Safety	+81.3%	N/A	N/A	N/A	N/A	+99.7%	N/A	N/A	N/A	+99.7%	N/A	+97.9%	N/A	N/A	N/A	N/A	N/A
Financial Basis	Annual history · FY 2025 · Balance sheet at 2026-07-31 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-07-31 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Annual history · FY 2025 · Balance sheet at 2026-07-31 · TTM ended 2026-07-31 vs 2025-07-31 · TTM ended 2026-07-31 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2025-12-22 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2025-12-22 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Market data at 2026-11-01 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2025 Latest source filing: 2025-12-22 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-07-31 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-07-31 · Qualitative assessment Latest source filing: 2026-09-08 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Market data at 2026-11-01 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-07-31 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment Latest source filing: 2025-12-22 Score computed: 2026-11-14	TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-07-31 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Annual history · FY 2025 · Balance sheet at 2026-07-31 Latest source filing: 2026-09-08 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-07-31 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-09-08 Score computed: 2026-11-14

Where It Passes

Valuation models100% pass✓ 4▾
ENGN undervalued: all 4 models price fair value above $2.41 (median $431.44)
Graham fair value$12.89
✓Graham+81.3% margin vs $2.41
Dreman fair value$774.85
✓Dreman+99.7% margin vs $2.41
Marks fair value$747.26
✓Marks+99.7% margin vs $2.41
Templeton fair value$115.62
✓Templeton+97.9% margin vs $2.41
Debt & Leverage58% pass✓ 10✗ 5▾
7 of 12 pass — Graham, Buffett, Lynch +2 more object
LT Debt vs Net Current Assets
✗GrahamLT Debt <= Net Current Assets
Debt/Equity & Interest CoverageD/E: 0.11, IC: -44.5x
✗BuffettD/E < 0.5 AND Interest Coverage > 5x
Total Debt / Equity0.11
✓Lynch< 0.33
Cash - Long-term Debt
✗LynchPositive preferred
LT Debt / Total Assets Change0.00% -> 0.00%
✓PiotroskiDecreased YoY
Current Assets / Current Liabilities10.21
✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
Total Debt / Shareholders' Equity0.11
✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
Debt Levels0.11
✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
Interest Coverage & Debt/EBITDAIC=-44.5x, D/EBITDA=N/A
✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
Total Debt / Shareholders Equity0.11
✓Ackman<= 1.0
Negative debt-to-equity (higher means less debt)-0.1101; #1326/4210 (top 31.5%)
✗AsnessTop 30% of eligible cross-section

Where It Falls Short

Growth0% pass✓ 1✗ 12▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)
✗Graham>= 33% growth
Basic earnings-growth PEG (dividends excluded)P/E 1.1x (growth N/A)
✗Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR-62.7%
✗Lynch15-30% (Fast Grower); > 0% to pass
Inventory Growth vs Revenue GrowthN/A (no inventory)
✓LynchInventory growth < Revenue growth
EPS Growth Direction$44.30 (2022) -> $2.29 (2025)
✗DremanPositive over recent years
EPS CAGR-62.7% CAGR over 3 years
✗Dreman> 5% annualized
Positive Net Income Frequency0/4 years positive
✗MarksPositive net income in >= 7 of last 10 years
3yr Median Revenue Growth
✗Ackman>= 5%
Positive EPS Growth Frequency2/3 years with positive EPS growth
✗AckmanPositive EPS growth in >= 3 of last 5 years
5-Year EPS CAGR-62.7% CAGR over 3 years
✗Templeton> 0% (5-year EPS CAGR)
Revenue growth vs. gross and operating margin trend
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
5-year Revenue CAGR
✗SleepCAGR > 7%
3-5 Year Diluted EPS CAGR-62.7% over 3 years
✗Neff7%-20% annualized
Verdicts0% pass✗ 13▾
Split decision: 12 FAIL · 4 NEUTRAL
Overall verdict
✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)✗GreenblattRank #2832✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (3/11)•MungerNEUTRAL (3/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
Profitability6% pass✓ 3✗ 32▾
15 of 16 flag ENGN's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)4/5 years positive
✗GrahamPositive EPS every year for 10 years
EPS Growth (3-yr avg, 10-yr window)
✗Graham>= 33% growth
Net Income Positive (10+ years)0/5 years positive
✗BuffettPositive every year for 10+ years
ROE (up to 5-year arithmetic mean)-76.0%
✗Buffett> 15% arithmetic mean (app rule)
Operating Margin (10-yr trend)
✗BuffettStable or rising over 10 years
Free Cash Flow Proxy$-117.3M
✗BuffettPositive and growing
Earnings Variance (10-yr CoV)
✗BuffettCoV < 0.3
Retained Earnings Effectiveness
✗Buffett$1 retained -> > $1 market value created
Basic earnings-growth PEG (dividends excluded)P/E 1.1x (growth N/A)
✗Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR-62.7%
✗Lynch15-30% (Fast Grower); > 0% to pass
ROE-56.6%
✗Lynch> 15%
EBIT / Enterprise Value-91.4%
✗Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=-91.4%, ROC=-101.2%
✗GreenblattBoth EY > 10% and ROC > 25%
Net Income / Total Assets-52.97%
✗PiotroskiROA > 0
ROA Change YoY-17.72% -> -52.97% (delta: -35.24%)
✗PiotroskiCurrent ROA > Prior ROA
(CFO / Total Assets) vs ROACFO/Assets=-44.81%, ROA=-52.97%
✓PiotroskiCFO/Assets > ROA
Gross Margin Change YoY
✗PiotroskiImproved YoY
Pre-Tax Income / Revenue
✗Dreman>= 8%
Net Income / Shareholders' Equity-56.6%
✗Dreman> 12%
Margin of SafetyP/E=1.1x
✓PabraiP/B < 1.5 or P/E < 15
Return on Equity-76.0% (3-yr avg)
✗AkreROE > 20% (3-year avg)
Discount to Intrinsic Value99.7% (IV=$774.85 vs Price=$2.41)
✓Marks>= 20% below intrinsic value
Positive Net Income Frequency0/4 years positive
✗MarksPositive net income in >= 7 of last 10 years
Operating Income / Revenue
✗Ackman>= 15%
Net Income / Shareholders Equity-56.6%
✗Ackman>= 15%
5-Year EPS CAGR-62.7% CAGR over 3 years
✗Templeton> 0% (5-year EPS CAGR)
Operating Margin Trend
✗TempletonNon-negative operating-margin trend over 3 years
Revenue growth vs. gross and operating margin trend
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
Net income / market capitalization-80.71%; #5283/6340 (top 83.3%)
✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
Gross profit / total assets
✗AsnessTop 30% of eligible cross-section
Net income / positive book equity-56.61%; #4289/5226 (top 82.1%)
✗AsnessTop 30% of eligible cross-section
Negative 5-year standard deviation of ROA-0.3895; #4783/5884 (top 81.3%)
✗AsnessTop 30% of eligible cross-section
3-5 Year Diluted EPS CAGR-62.7% over 3 years
✗Neff7%-20% annualized
Positive Diluted-EPS Years
✗Schloss>= 70% positive over 5-10 observed years (app rule)
Cash Flow10% pass✓ 2✗ 10▾
9 of 10 flag ENGN's cash flow — Buffett, Lynch, Piotroski +6 more
Free Cash Flow Proxy$-117.3M
✗BuffettPositive and growing
FCF Positive and Growing$-104.0M
✗LynchPositive and growing
Operating Cash Flow$-99.2M
✗PiotroskiCFO > 0
(CFO / Total Assets) vs ROACFO/Assets=-44.81%, ROA=-52.97%
✓PiotroskiCFO/Assets > ROA
Price / (CFO / Shares)
✗Dreman< 8x
P/E or FCF YieldP/E=1.1x, FCF Yield=-62.4%
✓PabraiP/E < 15 or FCF Yield > 10%
FCF Positive0/4 years FCF positive
✗MarksPositive FCF in majority of recent years
(OCF - CapEx) / Market Cap
✗Ackman>= 4%
Price / FCF per Share
✗Ackman<= 25
Positive Operating Cash Flow frequency0/4 years positive
✗SleepPositive OCF in >= 70% of available years
Operating Cash Flow - Capital Expenditures$-104.0M
✗Neff> $0 (app proxy for a strong fundamental case)
(Operating cash flow - capex) / market capitalization-64.39%; #3934/4519 (top 87.1%)
✗OshaughnessyTop 10% of eligible cross-section
Valuation23% pass✓ 9✗ 19▾
10 of 13 flag ENGN's valuation — Graham, Lynch, Greenblatt +7 more
Price / 3-yr avg EPS0.0x
✓Graham<= 15x
Price-to-Book Ratio
✗Graham<= 1.5x
P/E x P/B
✗Graham<= 22.5
Basic earnings-growth PEG (dividends excluded)P/E 1.1x (growth N/A)
✗Lynch< 1.0 (ideally < 0.5)
EBIT / Enterprise Value-91.4%
✗Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=-91.4%, ROC=-101.2%
✗GreenblattBoth EY > 10% and ROC > 25%
Price / EPS1.1x
✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
Price / (CFO / Shares)
✗Dreman< 8x
Price / Book Value per Share
✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
Valuation ReasonablenessP/E=1.1x
✓MungerP/E < 25 or Owner Earnings Yield > 5%
P/E or FCF YieldP/E=1.1x, FCF Yield=-62.4%
✓PabraiP/E < 15 or FCF Yield > 10%
P/B or P/E vs. Historical AverageP/E=1.1x
✓MarksP/E < 15 or P/B < 2.0
Discount to Intrinsic Value99.7% (IV=$774.85 vs Price=$2.41)
✓Marks>= 20% below intrinsic value
Price / FCF per Share
✗Ackman<= 25
Price vs. Trailing Low158% of trailing low ($1.53)
✗Templeton<= 120% of trailing low (certified split-adjusted live window)
Net income / market capitalization-80.71%; #5283/6340 (top 83.3%)
✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
Positive book equity / market capitalization+1.4259; #978/6449 (top 15.2%)
✓AsnessTop 30% of eligible cross-section
Price / Diluted EPS1.1x
✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
(EPS CAGR % + Dividend Yield %) / P/E
✗Neff> 0.7 (Neff's published traditional edge)
Price / Tangible Book Value per Share
✗SchlossP/TBV <= 1.00x (app cutoff)
Book Value per Share Change
✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
Revenue / market capitalization
✗OshaughnessyTop 10% of eligible cross-section
(Operating cash flow - capex) / market capitalization-64.39%; #3934/4519 (top 87.1%)
✗OshaughnessyTop 10% of eligible cross-section
Trailing six-month price return through the evaluation date+30.27%; #1012/6202 (top 16.3%)
✗OshaughnessyTop 10% of eligible cross-section
Efficiency25% pass✓ 2✗ 9▾
6 of 8 flag ENGN's efficiency — Buffett, Greenblatt, Piotroski +3 more
Current Ratio10.21
✓Graham>= 2.0
ROIC (3-5 yr avg)-59.1%
✗Buffett> 10%
ROIC - WACC-69.1%
✗BuffettPositive (WACC = 10%)
EBIT / (NWC + Net Fixed Assets)-101.2%
✗Greenblatt> 25%
Current Ratio Change YoY16.87 -> 6.30
✗PiotroskiIncreased YoY
Revenue / Total Assets Change YoY
✗PiotroskiImproved YoY
Current Assets / Current Liabilities10.21
✓Dreman> 1.5
Return on Invested Capital-42.2%
✗Munger> 15%
ROIC (high and growing)FY2023: ROIC=-28.2%; FY2024: ROIC=-18.0%; FY2025: ROIC=-50.9%
✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
Reinvestment Rate x ROICN/A (non-positive net income)
✗AkreReinvestment Rate * ROIC > 10%
ROIC (5-year)0/3 years above 12% (latest -50.9%)
✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products

SIC Sector: Chemicals & Pharmaceuticals

Size: Micro Cap($161.5M)

Revenue: N/A

Net Income: $117.3M-112.7% YoY

Financial Snapshot

Operating Margin--

Return on Equity-69.9%

Debt / Equity0.14

Current Ratio6.30

EPS (Diluted)$2.29

Similar Companies

MRKMerck & Co., Inc.

$364.3B

ABTABBOTT LABORATORIES

$188.0B

BMYBRISTOL MYERS SQUIBB CO

$129.7B

TECHBIO-TECHNE Corp

$11.4B

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

Metric	TTM · 2026-07-31 2025-08-01 – 2026-07-31 Sources · derived quarter values 10-K · 2025-12-22 10-Q · 2026-03-09 10-Q · 2026-06-15 10-Q · 2026-09-08 Derived from cumulative filings: net income, operating income, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.	Q3 FY 2026 2026-05-01 – 2026-07-31 Sources · derived quarter values 10-Q · 2026-09-08 Derived from cumulative filings: operating cash flow, capex.	Q2 FY 2026 2026-02-01 – 2026-04-30 Sources · derived quarter values 10-Q · 2026-06-15 Derived from cumulative filings: operating cash flow, capex.	Q1 FY 2026 2025-11-01 – 2026-01-31 Sources 10-Q · 2026-03-09	FY 2025 Sources 10-K · 2025-12-22	FY 2024 Sources 10-K · 2024-12-19	FY 2023 Sources 10-K · 2024-12-19	FY 2022 Sources 10-K · 2024-01-29	FY 2021 Sources 10-K · 2024-01-29
Market Cap	$161.5Mcurrent	--	--	--	--	--	--	--	--
Revenue	--	--	--	--	--	--	--	--	--
Operating Income	-$136.6M↓35%	-$34.0M↓14%	-$32.0M↓18%	-$31.2M↓17%	-$123.2M↓98%	-$62.3M↓139%	-$26.1M↓34%	-$19.4M	--
Net Income	-$130.4M↓38%	-$32.5M↓12%	-$30.2M↓17%	-$29.8M↓21%	-$117.3M↓113%	-$55.1M↑45%	-$99.9M↓308%	-$24.5M	--
EPS (Diluted)	--	$-0.47↓182%	$-0.43↓184%	$0.44↓8%	$2.29↑57%	$1.46↓99%	$151.22↑241%	$44.30	--
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
ROE	-56.6%↓20%	—	—	—	-69.9%↓246%	-20.2%↑85%	-137.8%↓532%	31.9%	—
Total Debt	$25.4M↑10%	$25.4M↑10%	$25.1M↑6%	$24.9M↑7%	$23.3M↑3237%	$699.0K↑24%	$562.0K↓97%	$18.7M	--
Shareholders' Equity	$230.3M↑15%	$230.3M↑15%	$255.2M↑12%	$281.5M↑13%	$167.7M↓38%	$272.6M↑276%	$72.5M↑195%	-$76.6M↓43%	-$53.4M
Current Ratio	10.21↓1%	10.21↓1%	12.57↓1%	11.75↓32%	6.30↓63%	16.87↑4%	16.25↑267%	4.42	—
Debt / Equity	0.11↓4%	0.11↓4%	0.10↓5%	0.09↓5%	0.14↑5324%	0.00↓67%	0.01↑103%	-0.24	—
Operating Cash Flow	-$103.3M↓10%	-$18.9M↑26%	-$30.5M↓33%	-$28.9M↓12%	-$99.2M↓106%	-$48.3M↓95%	-$24.7M↓41%	-$17.6M	--
Free Cash Flow	-$104.0M↓9%	-$18.9M↑28%	-$30.6M↓33%	-$29.1M↓12%	-$100.7M↓105%	-$49.2M↓96%	-$25.1M↓41%	-$17.7M	--

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

ENGN vs Peers — Financial Grading

RevenueN/A

Net Income$117.3MBottom 25%

ROE-69.9%Bottom 25%

D/E0.14Top 25%

Op. Margin—

Curr. Ratio6.30Top 25%

Company	Market Cap	Price	Revenue	Net Income	ROE	D/E	Op. Margin	Curr. Ratio	Graham	Buffett	Lynch	Greenblatt	Piotroski	Dreman
Merck & Co., Inc.MRK	$364.3B	$147.76	$65.0B	$18.3B	34.7%	0.94	—	1.54	2/9	5/9	4/7	0/3	F-Score 4	1/11
ABBOTT LABORATORIESABT	$188.0B	$108.52	$44.3B	$6.5B	12.5%	0.25	18.2%	1.58	3/9	4/9	2/7	1/3	F-Score 5	3/11
BRISTOL MYERS SQUIBB COBMY	$129.7B	$63.43	$48.2B	$7.1B	38.2%	2.44	19.4%	1.26	2/9	1/9	3/7	1/3	F-Score 8	5/11
BIO-TECHNE CorpTECH	$11.4B	$72.80	$1.2B	$73.4M	3.8%	—	8.4%	3.46	4/9	3/9	3/7	0/3	F-Score 5	4/11
REPLIGEN CORPRGEN	$10.7B	$167.79	$738.3M	$48.9M	2.3%	0.26	7.5%	8.37	3/9	2/9	3/7	0/3	F-Score 7	5/11
IONIS PHARMACEUTICALS INCIONS	$4.8B	$29.06	$943.7M	$381.4M	-78.0%	3.60	-40.4%	3.83	3/9	1/9	1/7	0/3	F-Score 4	3/11
NEOGEN CORPNEOG	$2.5B	$11.23	$870.4M	$7.9M	-0.4%	0.76	-2.5%	3.82	3/9	1/9	2/7	0/3	F-Score 6	4/11
Pharvaris N.V.PHVS	$2.4B	$33.36	—	$206.4M	-64.8%	0.00	—	—	0/9	0/9	2/7	0/3	F-Score 2	2/11